<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42CE62AA-63C7-447E-8692-AE40469EF4A2"><gtr:id>42CE62AA-63C7-447E-8692-AE40469EF4A2</gtr:id><gtr:firstName>Anatoli</gtr:firstName><gtr:surname>Kamali</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D591377-94F6-4E7B-AA14-CBE9743E6767"><gtr:id>3D591377-94F6-4E7B-AA14-CBE9743E6767</gtr:id><gtr:firstName>Rosalind</gtr:firstName><gtr:surname>Parkes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C02A0294-8267-4C18-AA4D-6186D308971D"><gtr:id>C02A0294-8267-4C18-AA4D-6186D308971D</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Lalloo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950085864"><gtr:id>10880500-FFEE-4B3B-9D86-6AFD52F05E13</gtr:id><gtr:title>HIV Care Research Programme / Primary Prevention of Invasive Cryptococcal Disease (CRYPTOPRO Trial)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950085864</gtr:grantReference><gtr:abstractText>Cryptococcal disease (a fungus infection) has been documented as a frequent infection among patients with advanced HIV progression in Africa. The disease can in principle be treated with fluconazole, but treatment is often unsuccessful and cryptococcal disease often ends fatal. It would therefore be helpful if a cost-effective prophylactic intervention strategy could be found. This would help both those patients who cannot access ART, and those who wait to start ART or just have started it (but have not yet regained their immuno-competence). It has been postulated that regular fluconazole medication may be a good prophylactic strategy against cryptococcal disease. Our study is a randomised placebo controlled trial to explore the effectiveness of this strategy.</gtr:abstractText><gtr:technicalSummary>Purpose: To determine if routine fluconazole prophylaxis in HIV infected Ugandans can reduce morbidity and mortality from invasive cryptococcal disease. Cryptococcal disease has been documented as an important optimistic infection in HIV infected patients in Africa and is associated with high mortality. The research question is relevant both for patients who are waiting to begin antiretroviral therapy (ART) and for those on ART who have not yet regained immune competence.||Methods: This is a double blind randomised placebo-controlled trial, with an original sample size of 590 HIV positive adults with CD4 counts less than 200 cells/microlitre, not (initially) on ART at enrolment, to be followed for 15 - 33 months. In 2006 the sample size was increased to 1420 to enable us including more patients who are about to start ART. Primary outcome measures are time to invasive cryptococcal disease or mortality attributable to cryptococcal disease. Secondary outcome measures include all cause mortality, time to first episode of symptomatic oro-pharyngeal candidiasis and time to first episode of oesophageal candidiasis. ||Participants are randomised to receive 200 mg fluconazole 3 times per week or placebo. They are routinely seen at 3-monthly intervals and can visit study clinics whenever ill. After enrolment participants are actively referred to ART outlets available in the study area. The project provides referral documentation on clinical and laboratory data to these services in order to facilitate the beginning of ART provision. Participants on ART stop taking trial drug (fluconazole or placebo) once their CD4 count is greater than 200 cells/microlitre.|</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1936381</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TASO</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>7DDBA894-924B-4122-9C31-4472F96E9BFA</gtr:id><gtr:impact>Trial results were presented to senior staff and the patient community of The AIDS Support Organisation (TASO) as well as to other local health care providers.

TASO now plans to provide fluconazole prophylaxis to all its eligible clients in Uganda.</gtr:impact><gtr:outcomeId>6EB4E8CD1B8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MoH policy on cryptococcal disease</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>12B959DB-B1FF-4A3A-9B9B-B4EA74398A33</gtr:id><gtr:impact>The MoH has received and discussed trial results. Policymakers at the MoH informed the researchers that they plan to revise current guidelines for HIV care in the light of the trial results.</gtr:impact><gtr:outcomeId>9B0F064BA1D</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Fluconazole prophylaxis</gtr:description><gtr:id>FEFAD36E-AD3A-4BA1-AF7B-EEC9CE433F63</gtr:id><gtr:impact>Reduction in incidence</gtr:impact><gtr:outcomeId>TB8zboAdCGh</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>CRYPTOPRO</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A research clinic suitable for clinical trials was establsihed in Masaka town within the premises of the Regional Hospital.</gtr:description><gtr:id>4B1739FE-8848-4993-8D46-EE6B2C9B7445</gtr:id><gtr:impact>The clinic is used for other studies; and will be used for a new trial funded by MRC, to commence in 2010.</gtr:impact><gtr:outcomeId>999D5D89A5E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>research clinic</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data, blood and other biological specimens were collected from about 1500 trial participants. These relate to clinical status and mortality, HIV and cryptococcal infection, haematological parameters, and liver and renal function tests.</gtr:description><gtr:id>CD2D353D-F075-43B3-B137-6D680EF851BB</gtr:id><gtr:impact>The research material was used to establish the effectiveness of fluconazole in preventing systemic cryptococcal disease.</gtr:impact><gtr:outcomeId>E314399AC07</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>crypto trial data base</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5A815AFB-935A-418D-B19B-3976687D4329</gtr:id><gtr:title>Symptom burden in HIV-infected adults at time of HIV diagnosis in rural Uganda.</gtr:title><gtr:parentPublicationTitle>Journal of palliative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9656df631da2183c1fe52a54c1392f46"><gtr:id>9656df631da2183c1fe52a54c1392f46</gtr:id><gtr:otherNames>Wakeham K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1557-7740</gtr:issn><gtr:outcomeId>ZGPXhMsfUDq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25DD4D21-BAD8-4849-86C1-4E8B123245A7</gtr:id><gtr:title>Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>qK3LeoVaSDa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>748C2147-E9EB-46D2-81F5-9BEC35BE43F9</gtr:id><gtr:title>Treatment of cryptococcal meningitis in resource limited settings.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7d8df257e748e69522231f52f1a1bc7"><gtr:id>a7d8df257e748e69522231f52f1a1bc7</gtr:id><gtr:otherNames>Sloan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>9FF40EBB4EB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>522B028F-80DB-4762-AEF4-BF6CCD53598C</gtr:id><gtr:title>Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9656df631da2183c1fe52a54c1392f46"><gtr:id>9656df631da2183c1fe52a54c1392f46</gtr:id><gtr:otherNames>Wakeham K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>01AC4359676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF75FC07-5036-4D0B-A517-E0B8FEABDD97</gtr:id><gtr:title>Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.</gtr:title><gtr:parentPublicationTitle>Journal of the International Association of Providers of AIDS Care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2325-9574</gtr:issn><gtr:outcomeId>56b0ded21558e6.70803800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5494C92C-CD43-4361-AFE4-BB9E59066DFE</gtr:id><gtr:title>Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>otMRhGRRnPb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0965D50-099E-46FA-ADA3-A48F181E2C2B</gtr:id><gtr:title>Use of nail and oral pigmentation to determine ART eligibility among HIV-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a812e4f1abe545f9b5ed7c881ce39f76"><gtr:id>a812e4f1abe545f9b5ed7c881ce39f76</gtr:id><gtr:otherNames>Namakoola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>mPJXwCvFN5P</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950085864</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>